The tweet was deleted by the author.
But we saved everything 🙂.
Nuvalent announced plans to present new clinical and preclinical data for its ROS1-positive non-small cell lung cancer (NSCLC) program at the AACR 2026 Annual Meeting in San Diego.
The upcoming presentation will provide updates on the development of targeted therapies for ROS1+ NSCLC, underscoring the company’s research momentum in oncology drug discovery. Further details on the specific data and clinical implications are expected to be revealed during the conference. Nuvalent’s participation highlights continued investment in next-generation treatments for difficult-to-treat cancers.